<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01541189</url>
  </required_header>
  <id_info>
    <org_study_id>CVAL489ACN14</org_study_id>
    <nct_id>NCT01541189</nct_id>
  </id_info>
  <brief_title>Double-dose Valsartan Monotherapy in Hypertension Treatment: an Effectiveness and Safety Evaluation in Chinese Patients.</brief_title>
  <official_title>A 8-week, Multi Center(10),Single Arm, Open-labeled Prospective Study of Valsartan 160 mg in 200 Mild to Moderate Chinese Hypertension Patients Forced Titrated From 2-week Therapy of Valsartan 80 mg.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate efficacy and safety of valsartan 160mg in Chinese hypertensive patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline and week 2 in blood pressure at week 10</measure>
    <time_frame>Baseline, 2 week and 10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of of patients who achieve BP&lt;140/90mmHg</measure>
    <time_frame>Baseline and 10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ABPM (Ambulatory Blood Pressure Monitor) at week 10</measure>
    <time_frame>Baseline and 10 weeks</time_frame>
    <description>Each subject will receive 24-hour ABPM at baseline and week 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HBPM (Home Blood Pressure Monitor) at week 10</measure>
    <time_frame>Baseline and 10 weeks</time_frame>
    <description>Each subject will receive HBPM at baseline, week 2, week 6 and week 10 respectively.For baseline HBPM, it was performed in the evening before visit 2 and in the morning of visit 2(before intake of study drug). in terms of the following 3 times of HBPM, they are performed during 5 days before each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events, serious adverse events</measure>
    <time_frame>during 10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>valsartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After 1-week screening period, all of the eligible patients receive valsartan 80mg/day for 2 weeks, then the dosage will be titrated to 160mg/day for further 8 weeks therapy for all of the subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>80 mg/day for 2 weeks, up-titrated to 160 mg/day for further 8 weeks</description>
    <arm_group_label>valsartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Naive primary hypertension patients or primary hypertensive patients on mono
             antihypertensive therapy:

          -  All treatment-naive patients need to have 140mmHg≤MSSBP&lt;180mmHg and 90mmHg≤MSDBP&lt;
             110mmHg at visit 1

          -  For patients on mono antihypertensive therapy, MSSBP/MSDBP should &lt;160/100mmHg at
             visit 1 (the beginning of screening period); and at visit 2(the beginning of
             theraputic period), they should have MSSBP≥140 mmHg and &lt;180mmHg AND MSDBP≥90 mmHg and
             &lt;110mmHg

        Exclusion Criteria:

          -  Severe hypertension

          -  Malignant hypertension

          -  Secondary hypertension

          -  Renal dysfunction(serum creatinine &gt; 2.0mg(176.8μmol/L)at visit 1)

          -  Hepatic disease

          -  History of hypertensive encephalopathy or cerebrovascular accident within 6 months

          -  History of myocardial infarction, coronary revascularization within 6 months

          -  Type 1 diabetes mellitus

          -  patietns with HbA1c &gt;8% at visit 1

          -  Women in pregnancy and lactation

          -  Potentially fertile female patients not using effective contraceptive methods

          -  Be allergy to study drug.

        Other protocol defined inclusion/exlusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=10943</url>
    <description>Clinical Trial Results for CVAL489ACN14 at Novartis Clinical Trials</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2012</study_first_submitted>
  <study_first_submitted_qc>February 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2012</study_first_posted>
  <last_update_submitted>March 17, 2017</last_update_submitted>
  <last_update_submitted_qc>March 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>valsartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

